You are here: Industry Insights > Olaparib

News List

Scottish Medicines Consortium approves three cancer drugs for NHS use Pharmaceutical-Technology
December 20, 2021
The Scottish Medicines Consortium (SMC) has approved three drugs for use on the National Health Service (NHS) Scotland to treat advanced ovarian, bowel cancer and Waldenström’s macroglobulinaemia.
NICE recommends olaparib tablets for platinum-sensitive cancer patients europeanpharmaceuticalreview
January 19, 2020
NICE has recommended olaparib tablets (Lynparza, AstraZeneca) for adults with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer with a BRCA1 or BRCA2 mutation.
FDA Approves olaparib for gBRCAm Metastatic Pancreatic Adenocarcinoma americanpharmaceuticalreview
January 03, 2020
The U.S. Food and Drug Administration (FDA) has approved olaparib (LYNPARZA®, AstraZeneca Pharmaceuticals) for the maintenance treatment of adult patients with deleterious or ...
Addition of Maintenance Olaparib Slows Advanced Ovarian Cancer drugs
December 19, 2019
Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with ...
NICE approves new tablet formulation for olaparib drug europeanpharmaceuticalreview
December 10, 2019
The UK NICE has extended its approval for olaparib, updating its formulation from eight capsules twice a day to two tablets twice daily.
Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer worldpharmanews
December 10, 2019
A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer ...
ASCO: Olaparib Beats Placebo for BRCA-Related Pancreatic Cancer drugs
June 05, 2019
Olaparib Beats Placebo for BRCA-Related Pancreatic Cancer.
Olaparib, Durvalumab for I-SPY 2 Trial Announces americanpharmaceuticalreview
September 10, 2018
Quantum Leap Healthcare Collaborative (QLHC) announced that a new randomized, investigational treatment arm for the I-SPY 2 TRIAL includes the study of olaparib and durvalumab, two agents from AstraZeneca.